지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 197 - 205 (9page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon α-2a therapy. The efficacy of and compliance to peginterferon α-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods:Hepatitis B patients treated with peginterferon α-2a from 2008to 2011 at four university hospitals were consecutively enrolled.
Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events.
At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients,10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period,15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon α-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals,but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
/ 2011 / Serum HBsAg Levels During Peginterferon alpha-2a Treatment With or Without Thymosin alpha-1 in HBeAg-Positive Chronic Hepatitis B Patients / JOURNAL OF MEDICAL VIROL
Buster EH / 2009 / Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa / Gastroenterology 137 : 2002 ~ 200
Chan HL / 2005 / A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone /
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Janssen HL / 2005 / Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / Lancet 365 : 123 ~ 129
Buster EH / 2009 / Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa / Gastroenterology 137 : 2002 ~ 200
Chan HL / 2005 / A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone /
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Janssen HL / 2005 / Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / Lancet 365 : 123 ~ 129
이 논문의 저자 정보
최근 본 자료
댓글(0)
0